卡托普利联合卡维地洛治疗原发性高血压的临床研究(1)
 |
| 第1页 |
参见附件(4282KB，5页)。
[摘要] 目的：探讨卡托普利联合卡维地洛治疗原发性高血压的临床疗效。方法：将2008年1月～2010年6月来我院治疗的160例原发性高血压患者随机分为观察组和对照组，每组80例，分别行卡托普利联合卡维地洛治疗和卡托普利治疗，疗程为8周，观察两组临床疗效、有关指标变化及不良反应等。结果：通过8周治疗，两组患者的血压均较治疗前降低(t=13.81、17.21、11.73、15.69、12.97、16.37、11.73、15.43、P<0.05)，且观察组血压下降的幅度高于对照组。观察组的总有效率(95.0%)和显效率(86.3%)显著高于对照组(75.0%、61.3%)，差异具有统计学意义(χ2=26.83、23.35，P<0.05)。结论：卡托普利联合卡维地洛治疗原发性高血压的临床疗效显著优于卡托普利单一用药，疗效确切、安全性好，值得临床大力推广。
[关键词] 卡托普利；卡维地洛；原发性高血压
[中图分类号] R972+.4 [文献标识码] A [文章编号] 1673-7210(2011)07(a)-072-03
Clinical research of Captopril and Carvedilo in the treatment of primary hypertension
HUANG Rui
The Third People's Hospital of Chenzhou City, Hu′nan Province, Chenzhou 423000, China
[Abstract] Objective: To investigate the clinical effect of Captopril and Carvedilo in the treatment of primary hypertension. Methods: 160 cases of essential hypertension patients in our hospital from January 2008 to June 2010 were randomly divided into observation group and control group, each group had 80 cases. Two groups were given Captopril ombine with Carvedilo and Captopril alone treatment respectively, the treatment course was 8 weeks. To observe the clinical effect, the relative index changes and the adverse reactions in two groups. Results: Blood pressure of two groups were obviously declined after 8 weeks treatment (t=13.81, 17.21, 11.73, 15.69, 12.97, 16.37, 11.73, 15.43, P<0.05), and the declining degree of observation group was higher than the control group. The total effective rate (95%) and efficiency rate (86.3) of observation group were higher than control group (75%，61.3%), and the relevant difference had statistical significance (χ2=26.83，23.35, P<0.05). Conclusion: The efficiency of Captopril combined with Carvedilo in treatment of essential hypertension is better than single captopril, which has exact effectiveness, security, and should be promoted.
[Key words] Captopril; Carvedilo; Primary hypertension
原发性高血压是一种最常见的心血管系统疾病，能够引起严重的脑、心、肾并发症，是冠心病和脑卒中的主要危险因素之一，高血压的治疗和控制应坚持长期用药原则，需要药物具有肯定的疗效和较小的副作用。卡托普利和卡维地洛分别为ACEI(血管紧张素转换酶抑制剂)和ARB(血管紧张素受体阻滞剂)类药物，本文将探讨两类药物联合使用的临床效果。
1 资料与方法 ......
您现在查看是摘要介绍页，详见PDF附件(4282KB，5页)。